PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Combining PD-L1 blockade with inhibition of oncogenic mitogen-activated protein kinase (MAPK) signaling may result in long-lasting responses in patients with advanced melanoma. This phase 1, open-label, dose-escalation and -expansion study (NCT02027961) investigated safety, tolerability and prelimin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribas, Antoni, Algazi, Alain, Ascierto, Paolo A., Butler, Marcus O., Chandra, Sunandana, Gordon, Michael, Hernandez-Aya, Leonel, Lawrence, Donald, Lutzky, Jose, Miller, Wilson H., Campbell, Katie M., Delafont, Bruno, Marshall, Shannon, Mueller, Nancy, Robert, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721806/
https://www.ncbi.nlm.nih.gov/pubmed/33288749
http://dx.doi.org/10.1038/s41467-020-19810-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721806/
https://www.ncbi.nlm.nih.gov/pubmed/33288749
http://dx.doi.org/10.1038/s41467-020-19810-w

Ejemplares similares